Predicting PD-L1 in Lung Adenocarcinoma Using 18F-FDG PET/CT Radiomic Features

被引:0
|
作者
Zhang, Huiyuan [1 ]
Meng, Xiangxi [2 ]
Wang, Zhe [3 ]
Zhou, Xin [2 ]
Liu, Yang [2 ]
Li, Nan [2 ]
机构
[1] Capital Med Univ, Beijing Chest Hosp, Beijing TB & Thorac Tumor Res Inst, Dept Nucl Med, Beijing 101149, Peoples R China
[2] Peking Univ, Minist Educ, Dept Nucl Med, Natl Med Prod Adm,Canc Hosp & Inst,Beijing Key Lab, 52 Fucheng Rd, Beijing 100142, Peoples R China
[3] Cent Res Inst, United Imaging Healthcare Grp, Shanghai 201900, Peoples R China
关键词
PD-L1; F-18] FDG; PET/CT; radiomics; lung adenocarcinoma; POSITRON-EMISSION-TOMOGRAPHY; CANCER; EXPRESSION; DOCETAXEL; INFORMATION; NIVOLUMAB; IMAGES;
D O I
10.3390/diagnostics15050543
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background/Objectives: This study aims to retrospectively analyze the clinical and imaging data of 101 patients with lung adenocarcinoma who underwent [F-18]FDG PET/CT examination and were pathologically confirmed in the Department of Nuclear Medicine at Peking University Cancer Hospital. This study explores the predictive value and important features of [F-18]FDG PET/CT radiomics for PD-L1 expression levels in lung adenocarcinoma patients, assisting in screening patients who may benefit from immunotherapy. Methods: 101 patients with histologically confirmed lung adenocarcinoma who received pre-treatment [F-18] FDG PET/CT were included. Among them, 44 patients were determined to be PD-L1 positive and 57 patients were determined to be PD-L1 negative based on immunohistochemical assays. Clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics were included in the modeling. Random Forest was used in feature denoising, while Forward Stepwise Regression and the Least Absolute Shrinkage and Selection Operator were used in feature selection. Models based on Tree, Discriminant, Logistic Regression, and Support Vector Machine were trained and evaluatedto explore the value of clinical data, PET/CT radiomics parameters, conventional metabolic parameters, and observed CT characteristics. Results: All models showed some predictive ability in distinguishing PD-L1 positive from PD-L1 negative samples. Among the multimodal imaging, clinical data were incorporated into the models, with clinical stage and gender selected by Forward Stepwise Regression, while clinical stage, smoking history, and gender were selected by LASSO. When incorporating clinical data and thin-section CT-derived images into the models, nodular type, spiculation, and CT Shape Flatness were selected by Forward Stepwise Regression, while nodular type and spiculation were selected by LASSO. When incorporating clinical data, PET/CT radiomics, observed CT characteristics, and conventional metabolic information. Forward Stepwise Regression selected TLGlean, MTV, nodule component, PET Shape Sphericity, while LASSO selected SULmax, MTV, nodular type, PET Shape Sphericity, and spiculation. Conclusions: The integration of clinical data, PET/CT radiomics, and conventional metabolic parameters effectively predicted PD-L1 expression, thereby assisting the selection of patients who would benefit from immunotherapy. Observed CT characteristics and conventional metabolic information play an important role in predicting PD-L1 expression levels.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Predicting EGFR mutation subtypes in lung adenocarcinoma using 18F-FDG PET/CT radiomic features
    Liu, Qiufang
    Sun, Dazhen
    Li, Nan
    Kim, Jinman
    Feng, Dagan
    Huang, Gang
    Wang, Lisheng
    Song, Shaoli
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (03) : 549 - +
  • [2] PD-L1 in Lung Adenocarcinoma: Insights into the Role of 18F-FDG PET/CT
    Cui, Yan
    Li, Xuena
    Du, Bulin
    Diao, Yao
    Li, Yaming
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 6385 - 6395
  • [3] Prediction of EGFR mutation status in lung adenocarcinoma based on 18F-FDG PET/CT radiomic features
    Tan, Jian-Ling
    Xia, Liang
    Sun, Su-Guang
    Zeng, Hui
    Lu, Di-Yu
    Cheng, Xiao-Jie
    AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 13 (05): : 230 - +
  • [4] Value of 18F-FDG PET/CT radiomic features to distinguish solitary lung adenocarcinoma from tuberculosis
    Yujing Hu
    Xinming Zhao
    Jianyuan Zhang
    Jingya Han
    Meng Dai
    European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48 : 231 - 240
  • [5] Predicting PD-1/PD-L1 status in bladder cancer with 18F-FDG PET?
    Emily B. Ehlerding
    Xiaoli Lan
    Weibo Cai
    European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 : 791 - 793
  • [6] Predicting PD-1/PD-L1 status in bladder cancer with 18F-FDG PET?
    Ehlerding, Emily B.
    Lan, Xiaoli
    Cai, Weibo
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (04) : 791 - 793
  • [7] Correlation between PD-L1 expression and glucose metabolic indexes of 18F-FDG PET/CT imaging of patients with lung adenocarcinoma
    Cui, Yan
    Li, Yaming
    Li, Xuena
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [8] Combination of clinical factors and PET/CT features can predict positive PD-L1 for patients with lung adenocarcinoma: a novel approach based on 18F-FDG PET/CT nomogram
    Xiao, Jie
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [9] Prediction model based on 18F-FDG PET/CT radiomic features and clinical factors of EGFR mutations in lung adenocarcinoma
    Zhao, Hong-Yue
    Su, Ye-Xin
    Zhang, Lin-Han
    Fu, Peng
    NEOPLASMA, 2022, 69 (01) : 233 - 241
  • [10] [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma
    Zhao, L.
    Chen, H.
    Lin, Q.
    Fu, K.
    Zhuang, Y.
    ANNALS OF ONCOLOGY, 2019, 30